Thank you for your message about CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies. You must verify your email address to receive further communication about this trial. Please check your email for a verification message.
We're sorry, your verification code has expired. Please submit another form using the button below to receive communications about your preferred clinical trial study.
Clinical Trial Study Email Verified CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies